| Trial Identifier: | D8850C00006 |
| Sponsor: | AstraZeneca |
| Start Date: | March 2022 |
| Primary Completion Date: | April 2024 |
| Study Completion Date: | April 2024 |
For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.
| Language | Description |
| English Version | |
| German Translation | |
| Spanish (US) Translation | |
| French (Belgium) Translation | |
| Dutch (Belgium) Translation | |
| Portuguese (Brazil) Translation |
| Country | Location |
|---|---|
| BE | Leuven, BE, 3000 |
| BR | Belo Horizonte, BR, 30130-100 |
| DE | Frankfurt am Main, DE, 60590 |
| GB | Southampton, GB, SO16 6YD |
| US, CA | Long Beach, CA, US, 90806 |
| US, CO | Aurora, CO, US, 80045 |
| US, DC | Washington, DC, US, 20007 |
| US, ID | Idaho Falls, ID, US, 83404 |
| US, NY | Stony Brook, NY, US, 11794 |
| US, RI | Providence, RI, US, 02903 |
| US, SC | Mount Pleasant, SC, US, 29464 |
Powered by
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.
Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company